YCM
KROS icon

Yiheng Capital Management’s Keros Therapeutics KROS Stock Holding History

Yiheng Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-554,151
Closed -$17.7M – 28
2023
Q3 		$17.7M Hold
554,151
– – 0.9% 19
2023
Q2 		$22.3M Hold
554,151
– – 1.2% 17
2023
Q1 		$23.7M Buy
+554,151
New +$28M 0.94% 18

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Yiheng Capital Management's KROS Position: Q4 2023 in Review

Yiheng Capital Management sold out of Keros Therapeutics (KROS) in Q4 2023, closing a stake of 554,151 shares — an estimated $17.7M sold.

Yiheng Capital Management first reported a position in KROS in Q1 2023 and held it in 3 quarters. The position peaked at $23.7M in Q1 2023. 121 funds tracked by Wall St. Rank hold KROS as of Q4 2023.

  • Yiheng Capital Management reported no remaining Keros Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Yiheng Capital Management sold 554,151 Keros Therapeutics shares in Q4 2023, an estimated $17.7M.
  • Yiheng Capital Management first reported a position in Keros Therapeutics in Q1 2023 and held it in 3 quarters.
  • Yiheng Capital Management's Keros Therapeutics position peaked at $23.7M in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2023.

Based on Yiheng Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.